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PRE-TRANSPLANT POSITRON EMISSION TOMOGRAPHY (PET) SCAN IS
NOT PREDICTIVE OF RELAPSE AND SURVIVAL IN NON-HODGKIN LYM-
PHOMA (NHL) PATIENTS UNDERGOING ALLOGENEIC TRANSPLANTA-
TION
Bachanova, V.1, Karagulle Kendi, A.T.2, Froelich, J.2, Cao, Q.1,
Celalettin, U.1, Burns, L.J.1 1University of Minnesota, Minneapolis,
MN; 2University of Minnesota, Minneapolis, MN
Allogeneic hematopoietic cell transplantation (HCT) is increas-
ingly used for patients with NHL. PET has become a standard for
lymphoma evaluation and a valuable prognostic tool to risk-stratify
treatments. The role of PET in the allogeneic HCT setting is con-
troversial.
This study investigated the value of PET status pre and at day 100
post HCT as a predictor of relapse and survival post allograft.
Seventy-eight patients with NHL received allogeneic HCT at the
University ofMinnesota from 2004-2009; 59 patients (median age 51
years) had pre-transplant PET evaluation and images were reviewed
centrally by nuclear medicine radiologist. Most patients were in re-
mission (33 PR, 17 CR) and 9 patients had chemo-refractory disease;
follicular lymphoma (n 5 26) was more common than diffuse large
B-cell (n 5 11), mantle cell (n 5 10) and other lymphomas (n 5
12). PET scan pre-transplant was positive in 38 patients (PET pos
group 64% vs PET neg group 36%). A third had PET-avid extra-
nodal involvement. Most patients received reduced intensity condi-
tioning (66%) and related donor or umbilical cord blood grafts (53%
and 46%, respectively).
3-year lymphoma-free survival (LFS) and overall survival (OS) of
the entire cohort were 52% (95%CI 38-64%) and 67% (95%CI 53-
78%). LFS andOS of the PETpos group was similar to the PETneg
group (52% vs 54%, p5 0.57; 68% vs 69%, p5 0.66; respectively).
In univariate analysis, extranodal PET positivity, .3 nodal sites in-
volved, elevated lactic dehydrogenase and marrow involvement pre-
transplant had no impact on OS or relapse rate.
At a median follow-up of 45months (range 12-81months); the cu-
mulative relapse rate at 1 year was 17% and was similar in PET pos
and PET neg groups (19% [95% CI 6-31%] vs 14% [95% CI 0-
29%]; p 5 0.59). Transplant mortality (TRM) at 1-year was low
for the entire cohort (15% [95%CI 6-24%]). PET status had no im-
pact on TRM and acute GVHD.
Forty-one patients had available surveillance PET evaluation at
day 100 post-transplant. The 1-year relapse rate and LFS were sig-
nificantly improved for those patient who were PET negative vs
PET positive (relapse 13% vs 42%; p 5 0.02; LFS 65% vs 25%,
p\0.01).
In conclusion, pre-allo HCT PET scan for NHL does not predict
transplant outcomes; however, a negative PET scan 100 days post-
allo HCT is a valuable tool prognostic of superior LFS. Studies eval-
uating role of PET in lymphoma subsets and development of novel
transplant interventions for patients with high relapse risk are war-
ranted.
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ALLOGENEIC STEM CELL TRANSPLANTATION IN 59 PATIENTS WITH
ADULT T-CELL LEUKEMIA/LYMPHOMA (ATLL) – A SINGLE CENTER’S
13 YEARS EXPERIENCE
Nakano, N., Takatsuka, Y., Takeuchi, S., Tokunaga, M., Kubota, A.,
Tokunaga, M., Itoyama, T., Makino, T., Utsunomiya, A. Imamura
Bun-in Hospital, Kagoshima, Japan
There were 59 (33 male, 26 female) ATLL patients who have con-
secutively undergone allo-SCT between June 1998 and March 2011
at Imamura Bun-in Hospital. Median age was 50 (range: 32-65)
years. Fifty patients were considered 0-1 of ECOG performance sta-
tus (PS) and rest of 9 were$2 at the time of SCT. Fifty-three patients
out of 59 were diagnosed as acute type ATLL, 5 lymphoma type, and
one chronic type with poor prognostic factors at the time of trans-
plantation, respectively. Stem cell sources were 36 BM (9 related do-
nors, 27 unrelated donors), 19 PB and 4CB, respectively. Thirty-five
patients received myeloablative conditioning (MAC) regimens and
24 reduced intensity conditioning (RIC) regimens. Forty-seven pa-S294tients out of 59 were used busulfan based non-TBI regimens. Sixteen
patients were in CR at SCT, and 43 non-CR (9 PR, 16 SD, and 18
PD), respectively. Cumulative incidence of ANC recovery ($500/
ml) was 98.2% after SCT. Probabilities of grade I to IV, II to IV acute
GVHDand chronicGVHDwere 71%, 44%, and 31%, respectively.
Interestingly, the incidence of CMV viremia, defined CMV-related
external matrix protein pp65-antigenemia positive in blood, after
SCT was extremely high (94.4%) in ATLL patient status post
SCT compared with reported other diseases. Overall survival (OS)
and disease free survival (DFS) at 2 years after SCT were 44.5%
and 32.5%, respectively. Notably, 2-yrs and 5-yrs OS in CR patients
were 72.7% and 48.5%, respectively. Cumulative incidence of re-
lapse at day100 and 1 year after SCT were 33.2% and 49.2% respec-
tively. Also cumulative incidence of non-relapse mortality (NRM) at
day100 after SCT was 20.4%. In univariate analysis, significant fac-
tors contributed to OS were CR status and 0-1 of PS at SCT, inci-
dence of acute and chronic GVHD, HLA matched donor, and
non-TBI regimens. CR status, 0-1 of PS at SCT, incidence of
chronic GVHD, BM, and HLAmatched donor were significant fac-
tors contributed to favorable outcome about DFS. MAC regimens
didn’t show favorable significance contributed to OS and DFS, but
reduce the incidence of early relapse compared with RIC regimen.
In multivariate analysis, incidence of chronic GVHD significantly
contributed to favorable outcome about OS and 0-1 of PS, incidence
of chronic GVHD and CR status contributed to favorable outcome
about DFS. In conclusion, allo-SCT can be feasible treatment for
ATLL and graft-versus-ATLL effect possibly exist given that
chronic GVHD was shown favorable survival factors.
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WT1-SPECIFIC T-CELL RESPONSES FOLLOWING T CELL-DEPLETED
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION AND DO-
NOR LYMPHOCYTE INFUSIONS IN PATIENTSWITH HIGH-RISKMULTIPLE
MYELOMA
Tyler, E., Jungbluth, A.A., O’Reilly, R.J., Koehne, G. Memorial Sloan-
Kettering Cancer Center, New York, NY
We are performing a clinical trial using T-cell depleted allogeneic
HSCT (TCD HSCT) from HLA compatible donors for patients
(pts) with relapsedmultiplemyeloma (MM) and high-risk cytogenet-
ics. Pts receive busulfan, melphalan, fludarabine and rabbit ATG fol-
lowed by allo TCDHSCT.T-cell depletion is performed by positive
CD34 selection achieving\104CD3+/kg for all grafts. Pts are eligi-
ble to receive low doses of donor lymphocyte infusions (DLI)
(5x10e5 – 1x10e6 CD3+/kg) no earlier than 5mos post TCDHSCT.
We evaluated the significance of WT1-specific cellular immune
responses following TCD HSCT and DLI in these pts. WT1-spe-
cific T-cell frequencies were determined in peripheral blood and
bone marrow specimens by staining for intracellular IFN-g produc-
tion in response to WT1 peptides, and/or by tetramer analysis,
where available.
Of 17 pts evaluated, all pts exhibited low frequencies ofWT1-spe-
cific T-cell responses pre TCD HSCT. Ten of these pts received
DLI postTCDHSCT.All 10 pts developed increasedWT1-specific
T cell responses postDLI. These increments inWT1-specificT-cell
frequencies were associated with reduction in specific myeloma
markers. Four pts with increasing M protein post TCD HSCT
achieved durable complete remissions post DLI in the abscence of
GvHD and are currently 18, 23, 24 and 40mos post allo BMT.
Long-term evaluation of these pts demonstrated fluctuations in per-
sisting WT1-specific T-cell frequencies following DLI.
In one representative pt, a peak of 3.5% (72/ml) WT1-specific
CD8+ T cells was detected in blood by staining with tetramer
HLA-A*0201 RMF. This peak T-cell response post TCD HSCT
and DLI coincided with disease regression. The pt has remained in
complete remission for more than 3 years post transplant, with levels
of WT1-specific CD8+ T cells ranging from 0.3-1.5% still persist-
ing. Findings from concurrent molecular chimerism studies con-
ducted on isolated T cells post TCD HSCT suggest that the
WT1-specific T cells are of donor origin.
Immunohistochemical analyses of WT1 and CD138 co-staining
in bone marrow specimens demonstrated consistent co-expression
within malignant plasma cells. In 6 pts tested, WT1 expression in
the bone marrow correlated with the extent of malignant plasma
Poster Session I S295cell infiltration. In contrast, no WT1 expression was observed when
disease was absent.
Our findings suggest an association between the emergence of
WT1-specific T cells and graft-versus-myeloma effect in pts being
treated for relapsed MM.246
UPFRONT TANDEM AUTOLOGOUS STEM CELL TRANSPLANT IS SUPERIOR
THAN AUTOLOGOUS OR ALLOGENEIC STEM CELL TRANSPLANT AFTER
FAILURE OF 1ST AUTOLOGOUS TRANSPLANT IN PATIENTS WITH MULTI-
PLE MYELOMA
Bachier, C., Wong, A., Shaughnessy, P., LeMaistre, C.F. Texas Trans-
plant Institute, San Antonio, TX
Disease progression remains the main cause of treatment failure
after autologous stem cell transplant (SCT) in patients with multiple
myeloma (MM). It is unclear what is the best salvage therapy after
failure of a 1st autologous SCT in MM.
We performed a retrospective study comparing 2nd autologous
(auto-auto) versus 2nd allogeneic (auto-allo) SCT in patients pro-
gressing or relapsing after their 1st autologous SCT and compare
their outcomes with patients receiving sequential planned double au-
tologous (tandem) SCT as part of their upfront therapy for MM.
The data was collected from CIBMTR reports and medical re-
cords at Texas Transplant Institute from 2001 to 2010. Patient’s
characteristics and outcomes are described in table. Response to 1st
and 2nd SCT was determined at 100 days post transplant and classi-
fied as good (stringent complete remission [sCR], complete remis-
sion [CR], very good partial remission [VGPR]) or poor (partial
remission [PR], stable disease [SD] or progressive disease [PD]).
All patients in the auto-allo group received a reduced intensity reg-
imen. The overall survival was calculated from the date of the 2nd
transplant to the known date of death in all groups. Patients in the
auto-allo group (15.9 months) had a worse median survival than in
the auto-auto group (39 months) with both of them having a worse
survival compared to patients undergoing tandem transplants
(64.3) (p value 5 0.003).
Forward stepwiseCox regression analysis was used tomeasure fac-
tors affecting overall survival. Factors used for analysis included age,
cytogenetics (high risk 5 mutated p53, t(14;16), t(4;14), del 13), In-
ternational Staging System (ISS) before 1st and 2nd SCT, use of
maintenance therapy after 1st SCT, days from diagnosis to 1st SCT
and days from 1st to 2nd SCT, CD34+ cells infused at 1st and 2nd
SCT. Age and ISS of III at 2nd transplant were identified as factors
affecting survival in the auto-auto group (hazard ration of 1.081
and 5.700, respectively).Table. Patient Characteristics and Outcomes
Tandem (n 5 29)
Median age, years (range) 62 (41-78)
Median days from diagnosis to 1st transplant 224.5 (93-1344)
Median days from 1st to 2nd transplant 149 (99-189)
Median total CD34+ cell infused 1st transplant 3.29 (2-12)
Median total CD34+ cell infused 2nd transplant 3.22 (2-9)
Median WBC engraftment 11 (9-13)
Median Platelet engraftment 16 (10-19)
Cytogenetics-High Risk 17%
ISS at 1st transplant I 31%
ISS at 1st transplant II 34%
ISS at 1st transplant III 14%
ISS at 2nd transplant I 48%
ISS at 2nd transplant II 17%
ISS at 2nd transplant III 10%
Response to 1st transplant Good 10%
Response to 1st transplant Poor 80%
Response to 2nd transplant Good 52%
Response to 2nd transplant Poor 80%
Median Followup (months) 57.1 (3.4-76.7)In conclusion, overall survival after salvage from 2nd autologous
stem cell transplant is longer than after a 2nd allogeneic transplant.
Upfront, planned tandem autologous stem cell transplant is superior
to both salvage strategies. Larger, randomized trials are needed to
confirm these results.247
RETROSPECTIVE REVIEW OF DPACE THERAPY AS A SALVAGE REGIMEN
IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA PRIOR TO AUTOLO-
GOUS STEM CELL TRANSPLANT
Snider, J.N.1, Stelts, S.D.2, Awan,M.3, Raza,M.3, Goorha, S.3 1Univer-
sity of Tennessee Health Sciences Center, Memphis, TN; 2Methodist
University Hospital, Memphis, TN; 3Boston Baskin Cancer Foundation,
Germantown, TN
Background: The landscape of multiple myeloma (MM) treatment
has improved substantially since the introduction of novel agents
thalidomide, bortezomib and lenolidomide. However, it is not al-
ways clear what therapy would be effective in patients after they
progress with these novel agents. To identify effective salvage ther-
apy, we performed a retrospective review of DPACE (dexametha-
sone, cisplatin, doxorubicin, cyclophosphamide, and etoposide)
chemotherapy in pretreated MM patients who were candidates for
autologous stem cell transplant (ASCT).
Methods: Review of electronic medical records at our institution
from January 1, 2005 to July 31, 2011 was performed. Eligible sub-
jects were $18 years old with a diagnosis of MM that received
DPACE after their disease had progressed with chemotherapy in-
cluding a novel agent and were transplant candidates. Data collected
included ISS stage at diagnosis, response to therapy, safety data, time
to transplant, and time to progression and death.
Results:We evaluated 24 patients who had received a median num-
ber of 2 (range 1-4) prior therapies, excluding single agent dexame-
thasone.Prior to DPACE, 38% (n 5 9) had undergone at least one
ASCT. The median number of DPACE cycles was 2 (range 1-5).
Median age was 57 (range 46 - 75); 75 % (n 5 18) were African-
American and 25% (n 5 6) were Caucasian. Partial response or
greater was achieved in 79% (n 5 19), stable disease in 13% (n 5
3), and 8% had progressive disease (n5 2). Dose reduction occurred
in 25% (n 5 6) of patients with dose reductions ranging from 20 to
50%. Sixteen patients (67%) proceeded to ASCT including five of
the 9 (55%) who had prior ASCT. Median time to transplant was
3 months (range 2 -11) from first DPACE cycle. Six patients experi-
enced CTCAE v4.0 grade 3/4 neutropenia with only 16% (n5 4) fe-
brile neutropenia. All patients received growth factor support. Grade
3/4 thrombocytopenia (n5 2), anemia (n5 2), and mucositis (n5 2)Auto-Auto (n 5 32) Auto-Allo (n 5 10)
62.5 (45-81) 54 (43-63)
226 (117-1074) 254.5 (101-416)
847 (210-4158) 350 (88-1281)
5.87 (2-28) 6.03 (2-14)
4.47 (2-19) 5.25 (3-11)
11 (9-47) N/A
15 (10-23) N/A
3% 10%
41% 40%
12% 0
6% 10%
53% 40%
9% 0
13% 10%
63% 70%
25% 20%
47% 30%
25% 20%
24.6 (10.5-87.8) 48.0 (31.9-64.0)
